^
    11ms
    A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC (clinicaltrials.gov)
    P1, N=42, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Jun 2023 | Trial primary completion date: Sep 2023 --> Jan 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)
    11ms
    A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1, N=19, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Jun 2023 | Trial primary completion date: Sep 2023 --> Jan 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)
    1year
    A study to evaluate the safety, tolerability, and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1–selected non–small-cell lung cancer (NSCLC): Updated efficacy and safety results. (ASCO 2023)
    With longer follow-up time, IBI939 plus sintilimab demonstrated durable PFS benefit and manageable safety profile in PD-L1 TPS ≥ 50% NSCLC patients with no prior systemic treatment. Clinical trial information: NCT04672369.
    Clinical • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)
    1year
    A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1a, N=34, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | N=270 --> 34 | Trial completion date: Dec 2023 --> May 2022
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)
    over1year
    A Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) (ESMO-IO 2022)
    The incidence of TRAEs was 85.7% vs 71.4% (2 and 5 pts experienced ≥ grade 3 events in each arm), respectively. The most common TRAEs were hypothyroidism (35.7%), aspartate aminotransferase increased (21.4%), blood urea increased (17.9%), hyperthyroidism (17.9%) in arm A. Immune-related AEs (determined by the investigator) were reported in 64.3% of pts in arm A and 50.0% of pts in arm B. Conclusions IBI939 plus sintilimab demonstrated improved PFS benefit and manageable safety profile in PD-L1 TPS ≥ 50% NSCLC patients with no prior systemic treatment.
    Clinical • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)
    over1year
    A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1a, N=270, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2021 --> Jun 2022
    Enrollment closed • Trial primary completion date • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)
    over3years
    A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    Clinical • New P1 trial • Combination therapy
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tyvyt (sintilimab) • tamgiblimab (IBI-939)